Nevakar Injectables can proceed with equivalents theory against Baxter, US judge says
( March 14, 2025, 10:10 GMT | Official Statement) -- MLex Summary: A US magistrate judge in Delaware agreed with Baxter Healthcare that allegations its norepinephrine product does not literally, directly infringe five Nevakar Injectables patents fail, but said factual disputes preclude summary judgment on Nevakar's infringement theory under the doctrine of equivalents.See attached document....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.